Beckman Coulter Diagnostics wins CE mark for Access p-Tau217 Alzheimer’s blood test in Europe

Danaher Corporation

Danaher Corporation

DHR

0.00
  • Danaher unit Beckman Coulter Diagnostics received CE Mark under IVDR for its Access p-Tau217 Alzheimer’s blood test in Europe.
  • Test targets amyloid pathology assessment in patients showing cognitive decline, aiming to broaden routine clinical adoption of blood-based biomarkers.
  • Beckman also launched Access BD-pTau217, a higher-specificity brain-derived pTau217 assay for research use only.
  • Both assays run on the DxI 9000 immunoassay analyzer, positioning a single platform for clinical testing alongside neurodegenerative research workflows.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Danaher Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607070300PR_NEWS_USPR_____LA98957) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.